Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | CCR4 | P51679 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 7/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709543 | 0.90 | GHSR (0.57) | GHSRHTR6CCR4KDM4ECACNA2D1 | |
| SCHEMBL1709599 | 0.89 | GHSR (0.56) | GHSRHTR6CCR4CACNA2D1MEN1 | |
| SCHEMBL1709541 | 0.87 | GHSR (0.61) | GHSRHTR6CCR4KDM4EPOLB | |
| SCHEMBL1709712 | 0.83 | GHSR (0.53) | GHSRHTR6CCR4MEN1KMT2A | |
| SCHEMBL1709622 | 0.82 | GHSR (0.52) | GHSRHTR6CCR4 | |
| SCHEMBL1994659 | 0.82 | GHSR (0.58) | GHSRHTR6CCR4KMT2A | |
| SCHEMBL1709653 | 0.81 | GHSR (0.53) | GHSRCCR4MEN1KMT2A | |
| SCHEMBL10121922 | 0.81 | GHSR (0.58) | GHSRCCR4SCN1ASCN2ASCN3A | |
| SCHEMBL1709708 | 0.81 | GHSR (0.67) | GHSRCCR4KDM4ESCN1ASCN2A | |
| SCHEMBL10121930 | 0.81 | GHSR (0.52) | GHSRCCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | GHSR 1/4885HTR6 764/4885CCR4 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.